Drug Trial Radar · NCT06801353
A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps
Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Feb 1, 2025
Primary completion
Dec 1, 2025
Study completion Jul 1, 2026
Sponsor
- Lead sponsor
- Beijing Tongren HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Recently, several biologic therapies have become available for treating chronic rhinosinusitis with nasal polyps (CRSwNP). However, not every patient responds to these treatments. This clinical trial aims to develop a non-invasive predictive model to help determine how effective IL-4Rα targeted monoclonal antibody therapy will be for individuals with CRSwNP.
Conditions
- Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
- Biological Therapy
- Biomarkers
Interventions
StapokibartBiological
Stapokibart subcutaneously every two weeks
Mometasone Furoate Nasal Spray (MFNS)Drug
mometasone furoate nasal spray 200 μg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Nasal Polyps Score (NPS)Time frame: week 16
- Nasal Congestion Score (NCS)Time frame: week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.